- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04782544
Ganglioside and IBD
Assessing Whether Buttermilk Powder Improves Disease Activity in Pediatric IBD
Context. Inflammatory bowel disease (IBD) is a chronic and debilitating disorder. Novel treatment strategies aimed to resolve intestinal inflammation and induce disease remission are necessary. Dietary gangliosides are safe for consumption, bioavailable, and have shown clinical benefit in patients with inflammatory intestinal disease.
Objectives. The primary objective is this study is to determine the efficacy of dietary ganglioside in improving disease activity indices in pediatric patients with IBD. Secondary objectives include demonstrating the effectiveness of dietary ganglioside for improving quality of life, improving intestinal integrity, and reducing inflammation.
Study Design. Intervention: controlled trial (pilot). Participants. Inclusion criteria: aged 9-21 years, diagnosis of ulcerative colitis (UC) or ileal or colonic Crohn Disease (CD), active disease. Exclusion criteria: pregnancy, inadequate liver or renal function, active infectious disease, previous bowel resection, disease remission, drug/alcohol abuse, other serious medical conditions, indeterminate colitis.
Study Intervention. Patients with IBD (n=48) will be allocated to consume ganglioside treatment or placebo daily for 10 weeks. Treatment group will consume five grams of buttermilk powder daily or anhydrous milk fat.
Outcome Measures. The primary outcome is the disease activity index: pediatric Crohn's Disease Activity Index (pCDAI) or pediatric Ulcerative Colitis Activity Index (pUCAI). Secondary outcomes include: quality of life (IMPACT-III questionnaire), intestinal permeability (lactulose/mannitol urinary assay), C-reactive protein (CRP; blood exam), calprotectin (fecal exam).
Expected Outcomes. Relative to the placebo group, the treatment group will have improved disease activity indices, quality of life, and intestinal integrity over the 10-week study period. The treatment group will also show reduction in inflammation and calprotectin relative to the placebo group.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Megan A Bailey
- Phone Number: 714-509-8869
- Email: mebailey@choc.org
Study Locations
-
-
California
-
Orange, California, United States, 92868
- Recruiting
- Children's Hospital of Orange County
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants age 9-21 years
- Mild-moderate IBD defined by ImproveCareNow (ICN) Physician Global Assessment (PGA); OR severe IBD defined by ICN PGA if stable for at least 120 days
- Ileal, ileocolonic, colonic location of disease
Exclusion Criteria:
- Pregnancy
- Previous bowel resection
- Non-ileocolonic location of disease
- Inadequate liver or renal function
- On prescription medication for active infectious disease
- Drug/alcohol abuse
- Other serious medical conditions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Treatment
5 grams of buttermilk powder daily for 10 weeks, oral.
|
Treatment with 5.0 g of buttermilk powder daily for 10 weeks.
|
PLACEBO_COMPARATOR: Placebo
5 grams of milk powder (10% buttermilk powder, 90% anhydrous milk fat) daily for 10 weeks, oral.
|
Treatment with 5.0 g of milk powder (90% anhydrous milk fat, 10% buttermilk powder) daily for 10 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease activity index
Time Frame: Day 0
|
Pediatric 1) Crohn Disease or 2) Ulcerative Colitis disease activity index
|
Day 0
|
Disease activity index
Time Frame: Day 70
|
Pediatric 1) Crohn Disease or 2) Ulcerative Colitis disease activity index
|
Day 70
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ImproveCareNow Physician Global Assessment
Time Frame: Day 0
|
A disease activity index
|
Day 0
|
ImproveCareNow Physician Global Assessment
Time Frame: Day 70
|
A disease activity index
|
Day 70
|
IMPACT-III questionnaire
Time Frame: Day 0
|
quality of life scales (0 = lowest, 100 = highest): well-being, emotional functioning, social functioning, body image
|
Day 0
|
IMPACT-III questionnaire
Time Frame: Day 70
|
quality of life scales (0 = lowest, 100 = highest): well-being, emotional functioning, social functioning, body image
|
Day 70
|
Intestinal integrity
Time Frame: Day 0
|
Intestinal permeability (lactulose/mannitol) challenge
|
Day 0
|
Intestinal integrity
Time Frame: Day 70
|
Intestinal permeability (lactulose/mannitol) challenge
|
Day 70
|
Calprotectin
Time Frame: Day 0
|
Stool test
|
Day 0
|
Calprotectin
Time Frame: Day 70
|
Stool test
|
Day 70
|
C-reactive protein
Time Frame: Day 0
|
Blood test
|
Day 0
|
C-reactive protein
Time Frame: Day 70
|
Blood test
|
Day 70
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hemoglobin, study start
Time Frame: Day 0
|
g/L, from metabolic panel
|
Day 0
|
Hemoglobin, study end
Time Frame: Day 70
|
g/L, from metabolic panel
|
Day 70
|
Platelets, study start
Time Frame: Day 0
|
#, from metabolic panel
|
Day 0
|
Platelets, study end
Time Frame: Day 70
|
#, from metabolic panel
|
Day 70
|
White blood cells, study start
Time Frame: Day 0
|
#, from metabolic panel
|
Day 0
|
White blood cells, study end
Time Frame: Day 70
|
#, from metabolic panel
|
Day 70
|
Albumin, study start
Time Frame: Day 0
|
g/L, from metabolic panel
|
Day 0
|
Albumin, study end
Time Frame: Day 70
|
g/L, from metabolic panel
|
Day 70
|
Hematocrit, study start
Time Frame: Day 0
|
proportion, from metabolic panel
|
Day 0
|
Hematocrit, study end
Time Frame: Day 70
|
proportion, from metabolic panel
|
Day 70
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 200109
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammatory Bowel Diseases
-
University of British ColumbiaCompletedInflammatory Bowel Disease 11Canada
-
University of ChicagoTerminatedInflammatory Bowel Disease (IBD)United States
-
Centre Hospitalier Universitaire, AmiensFunding from DGOS (PHRC IR 2013 and PRME)CompletedPediatric Inflammatory Bowel DiseaseFrance
-
University of Wisconsin, MadisonTerminatedInflammatory Bowel Disease (IBD)United States
-
Cedars-Sinai Medical CenterUnknownPediatric Inflammatory Bowel Disease
-
University of Wisconsin, MadisonCompletedInflammatory Bowel Disease (IBD)United States
-
Assiut UniversityNot yet recruitingIBD-Inflammatory Bowel Disease
-
Icahn School of Medicine at Mount SinaiNorthwestern University; The Cleveland Clinic; University of California, Davis; RxHealt...RecruitingInflammatory Bowel Disease (IBD)United States
-
Nemours Children's ClinicNASPGHAN FoundationCompletedInflammatory Bowel Disease (IBD)United States
-
Hull University Teaching Hospitals NHS TrustWellcome/EPSRC Centre for Interventional and Surgical Sciences, University...RecruitingInflammatory Bowel Disease 1United Kingdom
Clinical Trials on Buttermilk Powder
-
Laval UniversityDairy Farmers of CanadaCompletedCardiovascular DiseaseCanada
-
Maastricht University Medical CenterCompletedCardiovascular Disease | Hypercholesterolemia | Dietary Modification | ButtermilkNetherlands
-
Aimmune Therapeutics, Inc.TerminatedHen Egg AllergyUnited States
-
Mukuba UniversityUniversity of Stellenbosch; Medical Research Council, South AfricaCompleted
-
RiboCor, Inc.Completed
-
University of California, BerkeleyUniversity of California, DavisActive, not recruitingConsumption | Side Effect | AcceptabilityUnited States
-
GlaxoSmithKlineCompleted
-
Kantonsspital AarauTerminatedUrinary Tract InfectionsSwitzerland
-
Abbott NutritionCompleted
-
Johns Hopkins UniversityCompletedFood Hypersensitivity | Peanut Hypersensitivity | Immediate HypersensitivityUnited States